Skip to main content

PMR

New FDA Approved for Polymyalgia Rheumatica - Secukinumab

Jack Cush, MD

Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. This is the first anti-IL-17 biologic approved for

Dr. John Cush
@RheumNow
PMR: Spare The Steroids Please Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms. Jones calls you with a reported second PMR https://t.co/dbrdVZRuoN

PMR: Spare The Steroids Please

Daric A. Mueller, PA-C

Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms. Jones calls you with a reported second PMR symptom relapse at a 6 milligram

Janet Pope
@Janetbirdope
What happens in #PMR after d/c #secukinumab post 1 yr #Rx? Pts flare #secu 300mg flare 44% Secu 150mg 43% PBO 61.5% Time to flare more prolonged by 2 mo post 300mg secu withdrawal #ACR26 #1893 @ACRheum @RheumNow

3 x IL-23 = IL do Better (11.6.2026)

Jack Cush, MD

Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA. 

Dr. John Cush
@RheumNow
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic https://t.co/TPqPKP5MRl
×